BALTIMORE--(BUSINESS WIRE)--CraniUS^™, an R&D company focused on groundbreaking diagnostics and treatments for patients with chronic brain disease, has been awarded a competitive $1 million grant from the State of Maryland as part of Governor Wes Moore’s Build Our Future Innovation Infrastructure Pilot Program. This funding milestone – the first ever granted by the state program - will help CraniUS^™ expand its research capabilities, accelerate product development into human studies, and enhance its contributions to Maryland’s innovation ecosystem.

COLUMBIA, Md., June 25, 2024 — Welldoc^®, a leading digital health company specializing in AI-driven cardiometabolic health, today announced a collaboration with Instacart, the leading grocery technology company in North America, to transform healthcare delivery for health plans and members by bridging the gap between nutrition and health. Through enhanced access to quality care and nutritious food, Welldoc aims to improve health outcomes and reduce overall costs of care for individuals managing cardiometabolic conditions.

In Montgomery County, where incubator spaces are in high demand and existing facilities often have to turn away new entrepreneurs and startups, a new opportunity has emerged. Amador Bioscience’s recently announced incubator space in Germantown promises to help address this critical need, offering fledgling life sciences companies the space, resources and support they require to develop their projects beyond initial concepts.

Amador Bioscience is a translational and early clinical development partner for companies developing new drugs. Set within its existing but unused laboratory space in Germantown, Amador’s new incubator offers more than 10,500 square feet of lab and office space with state-of-the-art infrastructure designed to meet the diverse needs of life sciences startups.

Join us for a compelling episode of BioTalk with Rich Bendis as we welcome Dr. Michelle E. Tarver, Deputy Center Director and Chief Transformation Officer at the Center for Devices and Radiological Health (CDRH) at the US Food and Drug Administration (FDA). With a distinguished background as a board-certified ophthalmologist and epidemiologist, Dr. Tarver is at the forefront of transforming the evaluation and inclusion of medical devices in underserved and underrepresented populations.

In this episode, Dr. Tarver introduces the FDA and the CDRH Division, explaining the definition of a medical device by FDA standards. She discusses the creation of the Chief Transformation Officer role within the FDA, highlighting its importance and the strategic vision behind it.

Listen now via your favorite podcast platforms.

Apple: https://apple.co/3VFF5UK
Spotify: https://spoti.fi/3RC9sug
Amazon Music: https://amzn.to/4cdYqn8
TuneIn: https://bit.ly/4czGVO0

We explore the critical importance of diversity, equity, and inclusion (DEI) in evaluating medical devices, and how these efforts are essential for ensuring equitable healthcare for all. Dr. Tarver introduces the innovative “Home as a Health Care Hub” initiative by the FDA/CDRH, explaining its potential to revolutionize healthcare delivery.

ROCKVILLE, Md., June 24, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it initiated enrollment in a new cohort of patients ages 1-3 in its Phase I/II AFFINITY DUCHENNE^® trial to evaluate the safety and efficacy of RGX-202 in boys with Duchenne muscular dystrophy (Duchenne).

RGX-202 is an investigational one-time AAV Therapeutic targeted to deliver a novel microdystrophin, representing the next wave of innovative design in Duchenne gene therapy. RGX-202 is the only gene therapy approved or in development for Duchenne that incorporates the C-Terminal domain, making the RGX-202 transgene the closest to the naturally occurring dystrophin gene.

ROCKVILLE, Md. and SUZHOU, China, June 20, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the agreed equity investment by Takeda has been closed on June 20, 2024, with all proceeds already received. Pursuant to the terms of the Agreement, Ascentage Pharma has allotted and issued an aggregate of 24,307,322 subscription shares to Takeda International at the share purchase price of HK$24.09850 (equivalent to approximately US$3.08549).

GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has entered into a definitive agreement to sell its drug product facility in Baltimore-Camden to an affiliate of Bora Pharmaceuticals Co., Ltd. (“Bora”, TWSE: 6472), a leading international pharmaceutical services company, for a total value of approximately $30 million. The Camden site, which is part of Emergent’s Contract Development and Manufacturing Organization (CDMO), has clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services. Alongside the facility, approximately 350 current Emergent employees are expected to join Bora as part of the transaction.

Ianne Salvosa June 18, 2024 - Efforts are afoot to make Richmond more of a player in the biohealth industry.

Downtown-based Activation Capital is launching the Frontier BioHealth program to provide training and mentorship for up to 10 startups from August to November to groom life sciences companies in the area for the long term.

Activation Capital Vice President of Entrepreneurship Jim Pannucci said the program is a nod to the group’s original mission to help the region and the VA Bio+Tech Park be a hub of biotechnology. Activation Capital operates the park, while supporting entrepreneurship and startups in the region through various programs.

The Bio+Tech Park was established about three decades ago to turn Richmond into a center of biotechnology and now about 70 companies and research facilities operate in the area, with interests ranging from smoke-free tobacco alternatives to organ donation.

Small businesses can receive about $2 million to create a prototype and commercialize technology. 

The U.S. National Science Foundation has released new funding opportunities for its Small Business Innovation Research / Small Business Technology Transfer (SBIR/STTR) programs, increasing the maximum funding for SBIR/STTR Phase I awards to $305,000 and SBIR/STTR Phase II awards to $1,250,000 to further back development of the creative ideas coming from the nation's startups and small businesses. 

The SBIR/STTR program, also known as America's Seed Fund powered by NSF, provide non-dilutive funding for startups to develop deep technologies into commercially viable products and services with positive societal impact. The program focuses on companies at the earliest stage of development; most are newly emerging from the private sector, federal labs and academia. These entrepreneurs are taking scientific and engineering breakthroughs and translating them into new generations of products and services that are commercialized into sustainable businesses.  

Navigating the complex landscape of non-dilutive funding can be daunting for many innovators and researchers. Identifying suitable grants that align with specific project goals is often challenging, requiring a deep understanding of the funding landscape and specific program criteria.

We recognize these challenges at BioHealth Innovation (BHI) and are committed to supporting your journey. Our comprehensive grant mapping services are designed to pinpoint the most relevant funding opportunities tailored to your unique needs. With our expert guidance, you can confidently navigate the intricate world of grants, ensuring that your projects receive the support they deserve.

In addition to our grant mapping services, BHI offers dedicated SBIR/STTR grant writing assistance. Our team of seasoned professionals will work closely with you to craft compelling grant proposals that stand out to funding agencies. We understand the nuances and expectations of these programs, which significantly enhances your chances of success.

Partner with BHI to leverage our expertise and maximize your chances of securing the right non-dilutive funding for your innovative projects. With our support, you can focus on what you do best—innovating and pushing the boundaries of biohealth and life sciences

Let BHI be your trusted partner in navigating the funding landscape and unlocking the full potential of your groundbreaking work. If you're seeking assistance, don't hesitate to reach out toJon NelsonatThis email address is being protected from spambots. You need JavaScript enabled to view it..

BETHESDA, Md., June 17, 2024 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax^® personalized immune therapies for solid tumor cancers, announced today that on June 12, 2024 it entered into an exclusive license from Roswell Park Comprehensive Cancer Center for a portfolio of dendritic cell technologies and intellectual property (IP).  The technologies are already in Phase 2 clinical trials, and the Company plans to collaborate with the lead scientist-clinician, Dr. Pawel Kalinski, on the further development of the technologies.  The license is the culmination of more than 2 years of discussions and negotiations.

The license includes 5 new patent families that were just filed in 2023 and hence have their full potential patent life ahead of them.  The technologies include enhanced versions of dendritic cells (DCs) and DC based therapies, as well as conditioning regimens designed to enhance patient responses and approaches to reprogram the tumor microenvironment to boost immune therapies and help overcome resistance to checkpoint inhibitors.

Join us for an enlightening episode of BioTalk with Rich Bendis as we welcome Dan Berglund, President and CEO of SSTI. With nearly four decades of experience in tech-based economic development (TBED), Dan has been a pivotal figure in shaping the landscape of innovation and entrepreneurship across the nation.

In this episode, Dan shares the history and evolution of Technology Based Economic Development, discussing key initiatives in states like Ohio and Pennsylvania, and at the federal level. He highlights the importance of partnerships, detailing a compendium of state and federal cooperative technology programs that have driven progress in the field.

We explore the early years of SSTI, looking into its creation, mission, and initial goals, and how it has grown to support a nationwide network dedicated to fostering tech-based economies. Dan discusses the evolution and growth of state TBED programs, and the changing role of the federal government in supporting these initiatives through agencies like STCS, OSTP, Commerce, NIST, and EDA.

Listen now via:

Apple: https://apple.co/3RwdqEJ
Spotify: https://spoti.fi/3RrmIlh
Amazon Music: https://amzn.to/3vpZDHI
TuneIn: https://amzn.to/3xvGFjX

Dan also emphasizes the importance of private/public TBED partnerships, sharing insights into how these collaborations have bolstered economic growth and innovation. As he prepares to step down from his role after 28 years,and assume a part time role,  Dan discusses the recruitment of a new CEO and reflects on SSTI's achievements, his legacy, and his vision for the organization's future.

Additionally, Dan talks about Rich Bendis’s role as an original founding board member of SSTI, and his significant help in the early development of the organization. He also highlights the presence of several SSTI members in the BioHealth Capital Region.

College Park, Md.—The University of Maryland was spotlighted for its innovative curriculum and robust student engagement in entrepreneurship at the annual Deshpande Symposium on Innovation and Entrepreneurship in Higher Education held June 12-14 in College Park.

UMD was presented with the Entrepreneurial University Award, an annual honor given to an institution that exemplifies excellence in fostering an entrepreneurial culture across its campus.

“Students, faculty, staff and alums of the University of Maryland have a long and inspiring tradition of innovation that spans the arts, humanities and sciences – from Google and Beyond Meat to The Muppets and Under Armour,” said University of Maryland President Darryll J. Pines. “This award from the Deshpande Symposium will undoubtedly help our university build upon a distinguished past and present in innovation and entrepreneurship.”

By Tammi Thomas – Chief Development and Marketing Officer, TEDCO - Jun 17, 2024

Montgomery County, Maryland, is home to a thriving ecosystem of innovators and researchers who continuously work to enhance our daily experiences. TEDCO, the Maryland Technology Development Corporation, empowers these entrepreneurs by providing crucial funding and resources. Here's how four Montgomery County companies within TEDCO's portfolio are contributing to Maryland's quality of life and supporting a robust entrepreneurial landscape.

GERMANTOWN, MD / ACCESSWIRE / June 14, 2024 / Seraxis, Inc., a regenerative medicine company developing pancreatic islet replacement therapies to transform the lives of patients with Type 1 and insulin-requiring Type 2 diabetes, has been notified that the company is the awardee of a $400,000 Commercialization Program grant from the Maryland Stem Cell Research Fund (MSCRF) that aims to foster Maryland research to enhance and propel stem cell treatments. Seraxis will use the MSCRF grant to accelerate the validation and manufacturing of Seraxis' genetically modified pancreatic cell line (SR-03) that is designed to be a universal allogenic transplant that will not require lifelong anti-rejection immune suppression.

GAITHERSBURG, Md., June 14, 2024/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has submitted an amendment to its Emergency Use Authorization to the U.S. Food and Drug Administration (FDA) for its updated JN.1 COVID-19 vaccine (NVX-CoV2705) for individuals aged 12 and older. The submission is in line with guidance from the U.S. FDA, European Medicines Agency (EMA) and the World Health Organization (WHO) to target the JN.1 lineage this fall.^1-3 

Novavax's JN.1 vaccine has demonstrated broad cross-neutralizing antibodies against multiple variant strains, including KP.2 and KP.3, indicating the potential to protect against forward drift variants. As discussed at the recent FDA Vaccines and Related Biological Products Advisory Committee meeting, there is a public health benefit to target JN.1, the parent strain of the most common currently circulating variants.

ROCKVILLE, Md. and SUZHOU, China, June 14, 2024 /PRNewswire/ -- Ascentage Pharma (6855 HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today the signing of an option agreement with Takeda to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers. If exercised, the option would allow Takeda to license exclusive global rights to develop and commercialize olverembatinib in all territories outside of among others, mainland China, Hong Kong, Macau, Taiwan, China.

Despite the impact TKIs have had in the treatment of patients with CML, there remains a significant unmet need for patients whose disease is resistant to these therapies or who develop hard-to-treat mutations following these treatments.

COLUMBIA, Md., (June 13, 2024) — The Maryland Innovation Initiative (MII) Board of Directors announces the appointment of Abishek Kulshreshtha as the executive director of TEDCO’s MII program. In this position, Kulshreshtha will oversee all MII activities starting July 1, 2024.

As an independent unit within TEDCO, the Maryland Technology Development Corporation, MII was created to promote the commercialization of research conducted in five of Maryland’s academic research institutions (Johns Hopkins University; Morgan State University; University of Maryland, Baltimore; University of Maryland, Baltimore County; and University of Maryland, College Park) while leveraging each institution’s strengths. This collaborative program has supported more than 170 startup companies, created 370 jobs and procured more than $737 million in follow-on funding since its inception nearly 12 years ago.

WASHINGTON, June 13, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it has received a revised unsolicited proposal from Future Pak, LLC ("FP") to acquire Vanda for $8.50-$9.00 per share in cash plus certain Contingent Value Rights.

Consistent with its fiduciary duties, and in consultation with its financial and legal advisors, Vanda's Board will carefully review and evaluate the revised, non-binding proposal to determine the course of action that it believes is in the best interests of the Company and its shareholders.

ROCKVILLE, Md., June 12, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that Curran Simpson, Chief Operating Officer, has been appointed as President, Chief Executive Officer and a member of the Board of Directors, effective July 1, 2024. Co-Founder Kenneth T. Mills will step down as President and Chief Executive Officer following 15 years of leadership at the Company, and he is taking on an expanded role on the Board as Chairman. In connection with these changes, Board member Daniel Tassé has been appointed as REGENXBIO's Lead Independent Director, a role previously held by Jerry Karabelas, Ph.D. Dr. Karabelas and Co-Founder Allan Fox, who has served as Chairman since 2020, will remain on the Board.

Biotechnology company innovates treatment for pets with lumps, bumps and cancer

COLUMBIA, Md., (June 11, 2024) — TEDCO, Maryland’s economic engine for technology companies, announced a recent $200,000 Pre-Seed Builder Fund investment in Kubanda Cryotherapy. The Pre-Seed Builder Fund is housed under TEDCO’s Social Impact Funds, which were created to engage and invest in economically underserved founders and communities.

“Most pet tumors go untreated, and existing treatment options are inaccessible due to high costs and slow healing times,” said Bailey Surtees, CEO of Kubanda Cryotherapy. “We saw this gap in care and built an alternative, non-surgical solution, which offers less down time and better healing outcomes for pets. With TEDCO’s support, we can continue our mission of breaking down barriers to high-quality care.”

COLUMBIA, Md., (June 11, 2024) — Program Updates Unveiled for TEDCO’s Maryland Innovation Initiative TEDCO, Maryland’s economic engine for technology companies, announced recent changes to the Maryland Innovation Initiative (MII) program that will enhance efforts to support bringing innovative research to market. A collaboration between the State of Maryland and the five academic research institutions, MII’s goal is to foster the transition of promising technology and research developed in qualifying university labs to the commercial sector.

“With nearly 12 years of progress, research and continued support, we have witnessed several university researcher’s and faculty’s journey to commercial success,” said Renée Winsky, chair of the MII Board of Directors. “With these changes to our processes, we are confident that we will not only continue the overwhelming success but build on it.”

CHARLOTTESVILLE, VA / ACCESSWIRE / June 11, 2024 / KeViRx, Inc., an innovative, early-stage pharmaceutical company, announced today the receipt of $1.99 million in grant funding from the U.S. Department of Defense's Peer Reviewed Medical Research Program. This grant funding will allow KeViRx to advance its first-in-class small molecule platform technology, KVX-053, toward IND for pulmonary microvascular leakage and inflammation during acute lung injury (ALI). In the U.S., ALI affects 200,000 patients every year and can result from viral infection, sepsis, pneumonia or inhalation of chemical toxins. The most severe form of ALI is referred to as acute respiratory distress syndrome or ARDS.

"There are very limited treatment options for patients with ALI and 40% will die of ARDS," KeViRx Co-founder John S. Lazo said. "KVX-053 is a host-directed, insult-agnostic small molecule that targets the central pathways that are dysfunctional in ARDS. If we are successful, KVX-053 would be transformative for this disease."

BALTIMORE, MD, US, June 10, 2024 /EINPresswire.com/ -- Linshom Medical, a start-up medical device company was selected to present at the TechConnect World Innovation Conference on June 18, 2024 in Washington DC. After a competitive evaluation of over 100 applications, Linshom Medical was chosen as 1 of 13 companies to present at the Medical Threat Reduction Challenge, to an expert panel of judges, including federal funders, Medical CBRN Defense Consortium (MCDC) representatives, investors, and private corporations for a chance to earn a portion of $50,000 in non-dilutive prize money.

Linshom Medical is first to deliver an operating room quality respiratory profile to the patient bedside for continuous, predictive respiratory monitoring (CPRM). Recent data shows that the wearable, FDA cleared sensor provides health care providers 15 minutes of advance notice of respiratory decline compared to current standard of care. Clinical care team intervention during this early notice window is typically simple and inexpensive vs. the costly later alternatives when patients experience respiratory decline and are in trouble. These include rapid response activation, rescue events (codes), ICU transfers and potentially death.

-- Study Deepens Understanding of Treatments for Alzheimer’s Patients, Enabling More Effective Treatments --

POTOMAC, Md.--(June  10, 2024)--IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced the publication of a significant research article in the European Society of Medicine Journal. The study investigates the effects of CYP2C9 polymorphisms on the pharmacokinetics (“PK”) of delta-9-tetrahydrocannabinol (“THC”) and its active metabolite in Alzheimer’s disease (“AD”) patients.

The publication is titled “A study on CYP2C9 polymorphism in Puerto Rican Alzheimer's Patients and its role in the Pharmacokinetics of ∆-9-tetrahydrocannabinol” and is available at https://esmed.org/MRA/mra/article/view/5380.

PHILADELPHIA, June 07, 2024--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for the prevention of RSV lower respiratory tract disease (LRTD) in adults 50 through 59 years of age who are at increased risk. In the US, the vaccine is currently approved for use in adults aged 60 and older and recommended by CDC/ACIP using shared clinical decision-making.

OXFORD, United Kingdom, June 06, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a biopharmaceutical company developing novel T cell immunotherapeutic candidates, today announced the presentation of updated data from two clinical trials in people with chronic hepatitis B (CHB) at the European Association for the Study of the Liver (EASL) Congress 2024. The presentations include updated interim data from the Phase 2b clinical trial (HBV003), as well as new interim EOT data from the Phase 2a clinical trial (IM-PROVE II, AB-729-202) in partnership with Arbutus Biopharma (NASDAQ: ABUS), both in people with CHB receiving ongoing SoC NUC therapy.

ROCKVILLE, Md., June 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY). The collaboration will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody jointly developed by I-Mab and ABL Bio (KOSDAQ: 298380), with Bristol Myers Squibb's immune checkpoint inhibitor, nivolumab, and chemotherapy (FOLFOX or CAPOX), as a potential first-line treatment for patients with advanced Claudin 18.2-positive gastric and esophageal cancers.

REPROCELL USA is proud to announce that it has received funding from MSCRF for both proposals it has submitted for the MSCRF's January 2024 grant cycle. These two grants will help us produce Master Cell Banks (MCB) for cell therapy and enhance our capacity to produce therapeutic cell products.

BELTSVILLE, Md., June 5, 2024 /PRNewswire/ -- REPROCELL is a leader in producing clinically relevant human induced pluripotent stem cells (hiPSCs). These hiPSCs are generated from healthy donors that have been screened for eligibility using the questionnaire established by the US Food & Drug Administration (FDA). Further viral testing is performed to satisfy the requirements of FDA, European Medicines Agency (EMA) and Pharmaceutical and Medical Devices Agency (PMDA) of Japan. The first grant titled: "Generation of human iPSC and MSC MCBs and derivative products in an enclosed GMP system" will help REPROCELL offer two GMP grade cell lines in the next 8 to 12 months for commercialization. These products will be tested for quality and ready for off-the-shelf distribution and further differentiation internally, by other companies in Maryland and the rest of the world. This grant is funded by MSCRF under their commercialization grant that provides funding for commercializing the products.

Company Focused on Bringing Industry-Leading Technology to Market in Food Safety and MedTech Industries 

ALEXANDRIA, Va., June 5, 2024 /PRNewswire/ -- HyperSpectral, the world's first AI-powered spectral intelligence company with hardware-agnostic solutions for particle detection, emerged from stealth today with $8.5 million in a Series A funding round. HyperSpectral's Series A round was co-led by RRE Ventures and  Kibo Ventures with participation from Correlation Ventures, and GC&H Investments. The funds will allow the company to ramp up development of the technology, hire key talent, and create wider AI datasets through lab partnerships and testing.

Read more ...

Montgomery County, Maryland, is a top destination for the life sciences industry. Pete Briskman, JLL’s Executive Managing Director and Chair of BioHealth Innovation Inc.'s (BHI) Board of Directors, highlights several reasons why.

“Montgomery County is poised well in comparison to other regions,” Briskman said, pointing to its proximity to NIH and FDA and the strong talent pipeline from local universities.

Briskman also emphasized creative real estate solutions and the region’s strengths in cell and immunotherapy research. “Health care isn’t going away,” he noted, reflecting optimism about the sector's growth.

Washington, D.C., June 03, 2024 (GLOBE NEWSWIRE) -- Children’s National Hospital is pleased to welcome Alda Mizaku in a newly established role of vice president and chief data and artificial intelligence officer (CDAIO). In this role, Mizaku will lead the execution of enterprise data, analytics and artificial intelligence (AI) strategy at Children’s National.

Mizaku has a track record of leading initiatives with measurable organizational value, from reducing unnecessary length of stay to enhancing operational efficiency and patient outcomes. Prior to joining Children’s National, Mizaku spent 11 years working for Mercy Health System in St. Louis, where she served in various roles, including executive director of Data Engineering and Analytics, and vice president of Analytics Product Management.

Did you know? Each year, the federal government dedicates around $3.6 billion towards SBIR and STTR programs, resulting in awards to over 5,000 innovative projects!

The next deadline for NIH SBIR/STTR proposals is September 5th. As an innovation intermediary, BioHealth Innovation (BHI) is here to help you secure federal funding.

If you're seeking assistance, don't hesitate to reach out to Jon Nelson at This email address is being protected from spambots. You need JavaScript enabled to view it.. Let's innovate together!

At BioHealth Innovation Inc. (BHI), we are happy to celebrate the achievements of our partner company, miRecule, which has recently been named a winner at the INVEST Pitch Perfect competition. miRecule's innovative approach to RNA therapies represents a significant advance in the treatment of cancer and muscular dystrophy. By leveraging genomic data to design highly specific therapeutics, miRecule stands at the forefront of personalized medicine, underscoring our commitment to supporting ground-breaking healthcare solutions.

This recognition is not just a win for miRecule; it's a testament to the power of strategic partnerships and the impact of innovative biotechnological advances in addressing complex health challenges. BHI is proud to be associated with pioneers like miRecule, as we continue to foster a thriving ecosystem that brings revolutionary treatments from the lab to the patients who need them most.